S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NASDAQ:ANNX

Annexon (ANNX) Stock Forecast, Price & News

$3.13
+0.15 (+5.03%)
(As of 06/5/2023 ET)
Compare
Today's Range
$2.91
▼
$3.26
50-Day Range
$2.10
▼
$6.37
52-Week Range
$2.07
▼
$7.65
Volume
1.01 million shs
Average Volume
676,188 shs
Market Capitalization
$166.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.71
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Annexon MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
370.1% Upside
$14.71 Price Target
Short Interest
Healthy
5.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of Annexon in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$639,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.18) to ($1.98) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

103rd out of 985 stocks

Pharmaceutical Preparations Industry

39th out of 485 stocks

See Top Rated MarketRank™ Stocks Here

ANNX stock logo

About Annexon (NASDAQ:ANNX) Stock

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Receive ANNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter.

ANNX Stock News Headlines

June 1, 2023 | americanbankingnews.com
Bain Capital Life Sciences Inv Buys 300,000 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock
May 29, 2023 | americanbankingnews.com
Annexon, Inc. (NASDAQ:ANNX) Sees Significant Decrease in Short Interest
June 5, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
May 28, 2023 | americanbankingnews.com
Annexon (NASDAQ:ANNX) Cut to "Neutral" at JPMorgan Chase & Co.
May 27, 2023 | americanbankingnews.com
Annexon (NASDAQ:ANNX) Downgraded to "Neutral" at Bank of America
May 27, 2023 | americanbankingnews.com
Annexon (NASDAQ:ANNX) Price Target Cut to $7.00 by Analysts at BTIG Research
May 27, 2023 | americanbankingnews.com
Traders Buy High Volume of Put Options on Annexon (NASDAQ:ANNX)
May 26, 2023 | msn.com
B of A Securities Downgrades Annexon (ANNX)
June 5, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
May 26, 2023 | americanbankingnews.com
Annexon (NASDAQ:ANNX) Downgraded to Neutral at JPMorgan Chase & Co.
May 25, 2023 | seekingalpha.com
ACCD, GSIT and ANNX are among after hour movers
May 25, 2023 | markets.businessinsider.com
Analyst Expectations for Annexon's Future
May 25, 2023 | msn.com
Why Annexon (ANNX) Stock Is Getting Hammered
May 25, 2023 | msn.com
BTIG Maintains Annexon (ANNX) Buy Recommendation
May 25, 2023 | finance.yahoo.com
Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study
May 25, 2023 | finance.yahoo.com
Why Shares of Annexon Are Plummeting Thursday
May 25, 2023 | americanbankingnews.com
Annexon, Inc. (NASDAQ:ANNX) Receives Average Recommendation of "Moderate Buy" from Analysts
May 25, 2023 | markets.businessinsider.com
BTIG Reaffirms Their Buy Rating on Annexon Biosciences (ANNX)
May 25, 2023 | msn.com
Annexon Drops after Geographic Atrophy Candidate Disappoints
May 25, 2023 | seekingalpha.com
Annexon geographic atrophy candidate fails in phase 2; down 20%
May 17, 2023 | americanbankingnews.com
Analysts Issue Forecasts for Annexon, Inc.'s FY2023 Earnings (NASDAQ:ANNX)
May 17, 2023 | americanbankingnews.com
Annexon's (ANNX) Overweight Rating Reiterated at Cantor Fitzgerald
May 10, 2023 | americanbankingnews.com
Annexon (NASDAQ:ANNX) Releases Earnings Results, Hits Estimates
May 9, 2023 | finanznachrichten.de
Annexon Biosciences: Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
May 9, 2023 | marketwatch.com
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
May 9, 2023 | markets.businessinsider.com
Analyst Ratings for Annexon
May 9, 2023 | markets.businessinsider.com
Annexon Biosciences (ANNX) Gets a Buy from H.C. Wainwright
See More Headlines

ANNX Price History

ANNX Company Calendar

Last Earnings
5/08/2023
Today
6/05/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANNX
CUSIP
N/A
CIK
1528115
Web
www.annexonbio.com
Phone
650-822-5500
Fax
650-636-9773
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.71
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+354.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-141,950,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-66.42%
Return on Assets
-53.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.14
Quick Ratio
10.14

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.85 per share
Price / Book
0.67

Miscellaneous

Outstanding Shares
53,080,000
Free Float
42,940,000
Market Cap
$171.98 million
Optionable
Not Optionable
Beta
0.50

Key Executives

  • Mr. Douglas Love J.D.Mr. Douglas Love J.D. (Age 54)
    Esq., CEO, Pres & Director
    Comp: $830.99k
  • Dr. Larry C. Mattheakis Ph.D. (Age 65)
    Exec. VP & Chief Scientific Officer
    Comp: $296.45k
  • Dr. Ted Yednock Ph.D. (Age 64)
    Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board
    Comp: $614.6k
  • Dr. Arnon Rosenthal Ph.D. (Age 66)
    Founder
  • Ms. Jennifer LewMs. Jennifer Lew (Age 49)
    Exec. VP & CFO
  • Miriam Mason
    Sr. VP of Corp. Communications
  • Mr. Michael Overdorf M.B.A. (Age 52)
    Exec. VP & Chief Bus. Officer
  • Henk-Andre Kroon M.D.
    Sr. VP of Translational Medicine
  • Mirella Villa Del Toro
    Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ANNX Stock - Frequently Asked Questions

Should I buy or sell Annexon stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANNX shares.
View ANNX analyst ratings or view top-rated stocks.

What is Annexon's stock price forecast for 2023?

7 Wall Street research analysts have issued 12-month price targets for Annexon's stock. Their ANNX share price forecasts range from $3.00 to $30.00. On average, they predict the company's share price to reach $14.71 in the next twelve months. This suggests a possible upside of 354.1% from the stock's current price.
View analysts price targets for ANNX or view top-rated stocks among Wall Street analysts.

How have ANNX shares performed in 2023?

Annexon's stock was trading at $5.17 at the beginning of the year. Since then, ANNX stock has decreased by 37.3% and is now trading at $3.24.
View the best growth stocks for 2023 here.

Are investors shorting Annexon?

Annexon saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,040,000 shares, a decline of 13.6% from the April 30th total of 2,360,000 shares. Based on an average daily trading volume, of 486,900 shares, the short-interest ratio is presently 4.2 days. Currently, 5.7% of the company's shares are short sold.
View Annexon's Short Interest.

When is Annexon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ANNX earnings forecast.

How were Annexon's earnings last quarter?

Annexon, Inc. (NASDAQ:ANNX) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.52).

What ETFs hold Annexon's stock?

ETFs with the largest weight of Annexon (NASDAQ:ANNX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).iShares Neuroscience and Healthcare ETF (IBRN).

What other stocks do shareholders of Annexon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE).

When did Annexon IPO?

(ANNX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO.

What is Annexon's stock symbol?

Annexon trades on the NASDAQ under the ticker symbol "ANNX."

Who are Annexon's major shareholders?

Annexon's stock is owned by many different institutional and retail investors. Top institutional investors include Alerce Investment Management L.P. (13.29%), GMT Capital Corp (2.65%), Acadian Asset Management LLC (1.52%), Simplify Asset Management Inc. (1.23%), Geode Capital Management LLC (0.73%) and Renaissance Technologies LLC (0.67%). Insiders that own company stock include Bain Capital Life Sciences Fun, Bain Capital Life Sciences Inv, Douglas Love, James E Flynn, Jennifer Lew, Michael Overdorf, Muneer A Satter, Sanjay Keswani and Ted Yednock.
View institutional ownership trends.

How do I buy shares of Annexon?

Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Annexon's stock price today?

One share of ANNX stock can currently be purchased for approximately $3.24.

How much money does Annexon make?

Annexon (NASDAQ:ANNX) has a market capitalization of $171.98 million. The company earns $-141,950,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How can I contact Annexon?

The official website for the company is www.annexonbio.com. The company can be reached via phone at 650-822-5500, via email at swheeler@wheelhouselsa.com, or via fax at 650-636-9773.

This page (NASDAQ:ANNX) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -